Context Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. The company's innovative pipeline is anchored by three key programs: CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody; CT-95, a potential first-in-class mesothelin (MSLN) x CD3 bispecific antibody; and CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody. Context was organized in April 2015 under the laws of Delaware and is headquartered in Philadelphia, Pennsylvania.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, through Phase 1 dose escalation and expansion trials in patients with CLDN6-positive gynecologic and testicular cancers.
Expected impact: Establish safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity to support registrational pathways.
Advancing CT-95, an avidity-enhanced and affinity-tuned Mesothelin (MSLN) x CD3 bispecific T cell engager, through an ongoing Phase 1 clinical trial in patients with MSLN-expressing advanced solid tumors.
Expected impact: Demonstrate localized therapeutic activity in the tumor microenvironment while minimizing off-target effects from shed mesothelin.
Transitioning CT-202, a pH-dependent Nectin-4 x CD3 bispecific T cell engager, from preclinical development into first-in-human Phase 1 clinical trials.
Expected impact: Establish clinical proof-of-concept for a pH-dependent TCE designed to selectively target tumor tissues and avoid healthy tissue toxicities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures full economic rights to CT-202 by removing all future milestone and royalty obligations, allowing Context to capture maximum long-term value from the program.
Terms: Context paid a $4.5 million upfront payment in May 2026, with a second and final $2.0 million payment due by August 1, 2026, to buy out all future milestones and royalties.